in Featured, Medical Countermeasures, Research Countermeasure Development: First Ever FDA Qualification of Clinical Safety Biomarker
in Funding, Medical Countermeasures Soligenix’s Innate Defense Regulator Selected for NIH Commercialization Transition Funding
in Emerging Threats, Medical Countermeasures, Pathogens MERS-CoV: Clinical Trial Starts for Regeneron’s Monoclonal Antibody Treatments
in Emerging Threats, Medical Countermeasures Experimental MERS Antibody Therapeutics Enter Clinical Trial
